According to FutureWise analysis the market for triple-negative breast cancer treatment in 2023 was US$ 0.63 billion, and is expected to reach US$ 0.86 billion by 2031 at a CAGR of 3.9%.
Triple-negative breast cancer (TNBC) is a type of breast cancer that does not have estrogen receptors (ER), progesterone receptors (PR), or an excess of the HER2 protein. All three tests for these markers yield "negative" results. This form of cancer tends to affect women under the age of 40, particularly those who are Black or carry the BRCA1 mutation. TNBC is considered an aggressive type of cancer because it grows rapidly and is more likely to have spread by the time it is diagnosed. Additionally, it has a higher likelihood of recurrence after treatment compared to other breast cancer types. Most triple-negative tumors are classified as basal-like molecular subtypes, although the two terms are not entirely synonymous. Approximately 10-15% of all breast tumors are classified as triple-negative breast cancers.
HER2 positive/oestrogen receptor (ER) negative subtype and the basal-like subtype are two hormone receptor-negative subtypes of breast cancer that have been identified through gene expression studies. The luminal subtypes, which typically express hormone receptor-related genes, are another major subtype of breast cancer. The prognosis of the subtypes varies, with the two-hormone receptor-negative categories typically having worse results than the luminal divisions. The prognostic environment for breast cancer may alter, though, as a result of advancements in chemotherapy, endocrine therapy, and HER2-targeted therapy. Chemotherapy is the backbone of treatment for triple-negative breast cancer because it is resistant to hormonal treatments like tamoxifen and aromatase inhibitors as well as HER2-targeted medications like trastuzumab. The interest in this group of patients has grown as a result of the absence of targeted medicines.
According to the research study conducted by FutureWise research analysts, the Triple Negative Breast Cancer Treatment Market is anticipated to attain substantial growth by the end of the forecast period.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=249%20&type=requestsample
Triple Negative Breast Cancer Treatment Market Segmentation:
By Drug Type
- Doxorubicin
- Cyclophosphamide
- Paclitaxel
- Docetaxel
- Cisplatin/Carboplatin
- Others
By Distribution Channel
- Hospital Pharmacies
- Specialty Cancer Clinics
By Region
- Europe
- North America
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Triple Negative Breast Cancer Treatment Market:
- AstraZeneca PLC.
- Pfizer, Inc.
- F. Hoffman - La Roche Ltd.
- Bristol-Myers Squibb Company
- Novartis AG
- Mylan N.V.
- Eli Lilly and Company
- Celgene Corporation
- Sanofi S.A.
- Johnson & Johnson Services, Inc
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=249&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Triple Negative Breast Cancer Treatment Market By Drug Type, By Distribution Channel, and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
